Risk of cardiovascular events in patients at optimal values for combined lipid parameters

Current Medical Research and Opinion

Volumn 23, Issue 3, 2007, Pages 553-563

  Stanek, Eric J ^a   Sarawate, Chaitanya ^b   Willey, Vincent J ^b   Charland, Scott L ^a,c   Cziraky, Mark J ^b  

^a Kos Pharmaceuticals Inc   (United States)

^b HEALTHCORE INC   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Cardiovascular events; Lipids; Managed care; Population study

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DATA BASE; DISEASE CLASSIFICATION; EDUCATION PROGRAM; FEMALE; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; LABORATORY TEST; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; STROKE; TRANSIENT ISCHEMIC ATTACK;

AGE DISTRIBUTION; AGED; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COHORT STUDIES; FEMALE; HUMANS; HYPERLIPIDEMIAS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PRACTICE GUIDELINES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEX DISTRIBUTION; TRIGLYCERIDES;

EID: 33947378229     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X167660     Document Type: Article

References (67)

1. Adult Treatment Panel III. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. J Am Med Assoc 2001;285: 2486-97
2. Adult Treatment Panel III. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults [final report] Circulation 2002;106:3143-421
3. US Department of Health and Human Services Centers for Disease Control and Prevention. Preventing heart disease and stroke: addressing the nation's leading killers 2005. CDC 2005
4. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52
5. The 4S Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
6. Anon. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
7. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
8. Ford ES, Mokdad AH, Giles WH, et al. Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: findings from the National Health and Nutrition Examination Survey, 1999 to 2000. Circulation 2003;107:2185-9
9. Johnson CL, Rifkind BM, Sempos CT, et al. Declining serum total cholesterol levels among US adults. The National Health and Nutrition Examination Surveys. J Am Med Assoc 1993;269:3002-8
10. Kagan A, Harris BR, Winkelstein Jr W, et al. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: demographic, physical, dietary and biochemical characteristics. J Chronic Dis 1974;27:345-64
11. Keys A. Seven countries: a multivariate analysis of death and coronary heart disease. Cambridge (MA): Harvard University Press; 1980
12. Keys A, Menotti A, Aravanis C, et al. The seven countries study: 2289 deaths in 15 years. Prev Med 1984;13:141-54
13. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New Engl J Med 2005;352:1425-35
14. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results I: reduction in the incidence of coronary heart disease. J Am Med Assoc 1984;251:351-65
15. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results II: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. J Am Med Assoc 1984;251:365-74
16. Lloyd-Jones DM, Larson MG, Beiser A, et al. Lifetime risk of developing coronary heart disease. Lancet 1999;353:89-92
17. McGill Jr HC. Introduction to the geographic pathology of atherosclerosis. Lab Invest 1968;18:465-7
18. Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. New Engl J Med 1990;322:1700-7
19. Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. New Engl J Med 1990;323:1112-9
20. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). J Am Med Assoc 1986;256:2823-8
21. Toor M, Katchalsky A, Agmon J, et al. Atherosis and related factors in immigrants to Israel. Circulation 1960;22:265-79
22. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47
23. Wong ND, Wilson PW, Kannel WB. Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study. Ann Intern Med 1991;115:687-93
24. Wiviott SD, Cannon CP, Morrow DA, et al. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 2005;46: 1411-6
25. de Lemos JA, Wiviott SD, Murphy SA, et al. Evaluation of the National Cholesterol Education Program Adult Treatment Panel III algorithm for selecting candidates for statin therapy: insights from the A to Z trial. Am J Cardiol 2006;98: 739-42
26. Deedwania P, Barter P, Carmena R, et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 2006;368:919-28
27. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. J Am Med Assoc 2005;294:2437-45
28. Charland SL, McGovern ME, Stanek EJ. Diminishing rates of return in reducing coronary heart disease event rates with progressive LDL cholesterol lowering: linear vs inhibitory maximum effect modeling. Circulation 2005;112:816
29. Assmann G, Schulte H, Funke H, et al. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 1998;19(Suppl M):M8-M14
30. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998;81:7B-12B
31. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15
32. Wilson PW, Garrison RJ, Castelli WP, et al. Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols. Am J Cardiol 1980;46:649-54
33. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. New Engl J Med 2001;345:1583-92
34. Rubins HB, Robins SJ, Collins D. The Veterans Affairs High-Density Lipoprotein Intervention Trial: baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol [Veterans Affairs Cooperative Studies Program High-Density Lipoprotein Intervention Trial Study Group]. Am J Cardiol 1996;78: 572-5
35. Rubins HB, Robins SJ. Conclusions from the VA-HIT study. Am J Cardiol 2000;86:543-4
36. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-7
37. Blankenhorn DH. Prevention or reversal of atherosclerosis: review of current evidence. Am J Cardiol 1989;63:3 8H-41H
38. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. New Engl J Med 1990;323:1289-98
39. Rubins HB, Robins SJ, Collins D, et al. Distribution of lipids in 8500 men with coronary artery disease [Department of Veterans Affairs HDL Intervention Trial Study Group]. Am J Cardiol 1995;75:1196-201
40. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 2006;22:2243-50
41. Bullano MF, Kamat S, Willey VJ, et al. Agreement between administrative claims and the medical record in identifying patients with a diagnosis of hypertension. Med Care 2006;44: 486-90
42. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9
43. Hebert PL, Geiss LS, Tierney EF, et al. Identifying persons with diabetes using Medicare claims data. Am J Med Qual 1999;14:270-7
44. Yu Y, Bullano MF, Willey VJ. Evaluating the diagnostic validity of administrative claims data for common chronic diseases. Value Health 2005;8:267
45. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
46. Siddiqui O, Ali MW. A comparison of the random-effects pattern mixture model with last-observation-carried-forward (LOCF) analysis in longitudinal clinical trials with dropouts. J Biopharm Stat 1998;8:545-63
47. Streiner DL. The case of the missing data: methods of dealing with dropouts and other research vagaries. Can J Psychiatry 2002;47:68-75
48. Gillings D, Koch G. The application of the principle intention to treat analysis of clinical trial. Drug Infect J 1991;5:411-24
49. Rosner B. Fundamentals of biostatistics. Brooks/Cole; 2000
50. Hosmer DW, Hosmer T, Le Cessie S, et al. A comparison of goodness-of-fit tests for the logistic regression model. Stat Med 1997;16:965-80
51. Anon. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
52. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Br Med J 1994;308:367-72
53. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Br Med J 2003;326:1423
54. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to parvastatin vs usual care: the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). J Am Med Assoc 2002;288:2998-3007
55. Assmann G, Schulte H, von Eckardstein A, et al. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996;124(Suppl):S11-S20
56. Hulley SB, Rosenman RH, Bawol RD, et al. Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease. New Engl J Med 1980;302:1383-9
57. Sprecher DL, Waddns TR, Behar S, et al. Importance of high-density lipoprotein cholesterol and triglyceride levels in coronary heart disease. Am J Cardiol 2003;91:575-80
58. Wilson PW, D'Agostino RB, Nam BH, et al. Categories of dyslipidemia and risk of cardiovascular disease. Circulation 2005;111:244
59. Foley KA, Massing MW, Simpson Jr RJ, et al. Population implications of changes in lipid management in patients with coronary heart disease. Am J Cardiol 2004;93:193-5
60. Latts LM. Assessing the results: phase 1 hyperlipidemia outcomes in 27 health plans. Am J Med 2001;110(Suppl 6A): 17S-23S
61. Pearsons T, Peters T, Feury D. Comprehensive risk reduction in coronary patients: attainment of goals of the AHA guidelines in U.S. patients [abstract]. Circulation 1997;96
62. Capuzzi DM, Morgan JM, Weiss RJ, et al. Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. Am J Cardiol 2003;91:1304-10
63. Guyton JR, Goldberg AC, Kreisberg RA, et al. Effectiveness of once-nighdy dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 1998;82:737-43
64. Brown B. Maximizing coronary disease risk reduction using nicotinic acid combined with LDL-lowering therapy. Eur Heart J Suppl 2005;7(Suppl F):F34-F40
65. Whitney EJ, Krasuski RA, Personius BE, et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events (AFREGS). Ann Intern Med 2005;142:95-104
66. Tierney WM, McDonald CJ. Practice databases and their uses in clinical research. Stat Med 1991;10:541-57
67. D'Agostino RB, Grundy S, Sullivan LS, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. J Am Med Assoc 2001;286:180-97